WHEN?
Sep/18/2024 - Sep/20/2024We’re excited to announce our participation in the upcoming qNMR Summit Buchs 2024 as GOLD sponsors!
Join us at this event to learn more about Mestrelab’s latest developments in qNMR software solutions. We’re also looking forward to sharing our insights through a presentation by our colleague Dr. Haris Panagos “Making complex spectra simple to analyze with USP-ID” Software Session on Tuesday 17 at 9.50am
We hope to see you in Buchs!
When?
September 18 – 20, 2024
Where?
BZBS Mehrzweckhalle,
Hanflandstrasse 17, 9470 Buchs SG, (St. Gallen), CH
Are you struggling with qNMR analysis and need a reliable and efficient solution?
Check out our latest qNMR module called USP-ID. this software combines high-quality chemical reference databases with smart algorithms for one-click, automated solutions by qNMR, giving scientists the tools to identify and quantify complex chemical mixtures. Would you like to talk about it? Contact us in advance!
Mnova qNMR is also here to help. Our software streamlines the qNMR analysis process, allowing you to quickly and accurately determine the concentration of your sample.
We also understand the importance of sample purity and accurate concentration determination, which is why we’ve developed Gears Purity and Gears Concentration. Gears Purity provides advanced purity analysis, including peak purity and purity profiling, giving you a detailed understanding of your sample’s purity. Gears Concentration enables accurate concentration determination, even in complex mixtures.
Don’t let qNMR analysis slow you down. Click on the links above to learn more about our software solutions tailored to your needs.
Success Stories
Case Studies
Automated qNMR data processing and analysis in the behind the scenes of fragment-based drug discovery
Bringing new drugs into the market is a long, complex process that often requires several years of investigation and considerable human, technological, and economic resources. In the labs of the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, a Fragment-Based Drug Discovery (FBDD) program has been established for screening and identifying lead compounds with potential therapeutic effects that may serve as starting points for the development of potent drug candidates… Read More
